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Abstract
Background: Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) have modulating effects in several chronic infl amma-
tory conditions. The aim of the present study was to test whether prior short-term dietary supplementation with n-3 (fi sh or 
seal oil) or n-6 (soy oil) PUFA rich oils would protect the development of dextran sulfate sodium (DSS)-induced colitis in 
rats. 
Methods: Forty-eight male Wistar rats were divided into 6 groups: no intervention, sham, DSS, seal oil + DSS, fi sh oil + 
DSS and soy oil + DSS. Following 7 days of acclimatisation, 1 mL oil (seal, fi sh or soy) or distilled water (sham) was 
administered by gavage day 8 to 14. Colitis was induced by 5% DSS in drinking water from day 15 to 21. Rats were sacri-
fi ced on day 23. Histological colitis (crypt and infl ammation) scores, faecal granulocyte marker protein (GMP) and quan-
titative fatty acid composition in red blood cells were measured.
Results: Pretreatment with fi sh or seal oils did not signifi cantly infl uence DSS induced infl ammation. In fact, all the oils 
tended to exacerbate the infl ammation. Soy oil increased the mean crypt score (P < 0.04), but not the infl ammation score 
or GMP. The ratio of n-6 to n-3 fatty acids (FAs) was 11 to 1 and 10 to 1 in standard diet and in red blood cells of control 
rats, respectively. Following administration of DSS, the ratio fell in all treatment groups (P < 0.001). The lowest ratios were 
seen in the groups receiving DSS + fi sh or seal oils (around 6 to 1).
Conclusion: Short-term pretreatment with fi sh or seal oils did not protect against subsequent induction of colitis by DSS 
in this rat model. Whether the high ratio of n-6 to n-3 FAs in the standard diet concealed effects of n-3 FA supplementation 
should be further investigated.
Keywords: Colitis; dextran sulfate; seal oil; fi sh oil; soy oil; ratio omega-6 to omega-3; rats.
Introduction
Infl ammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), 
is characterised by increased mucosal production of several eicosanoids, such as prostaglandin (PG) 
E2, thromboxane A2, prostacyclin I2 and leukotriene ( LT) B4 (1). Recently, dietary supplementation 
with omega-3 (n-3) polyunsaturated fatty acids (PUFAs) to IBD patients has received considerable 
interest because these fatty acids (FAs) have the potential to modify eicosanoid production and infl am-
mation. However, the results of clinical trials are equivocal (2, 3).
In some prior studies, increased dietary intakes of n-3 FAs led to biochemical, histological and 
clinical improvements, both in patients with IBD and in experimental models of colitis (4–6). In one 
animal model, even maternal dietary n-3 FA supplementation impaired the development of colitis in 
the offsprings (7). However, a recent retrospective multicenter case-control study reported that total fat 
and fat-related nutrients, including monounsaturated FAs and PUFAs, vitamin E, and n-3 and n-6 FAs 
increased the risk for IBD, particularly for CD (8).
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The inhibited production of metabolites of 
arachidonic acid, especially products of the 5-
lipoxygenase pathway, LTB4, is considered the most 
important mechanism by which n-3 FAs infl uence 
infl ammation (9). The general rule is that eico-
sanoids derived from n-3 PUFAs are less potent 
triggers of immunological and infl ammatory reac-
tions, compared to the corresponding compounds 
derived from n-6 PUFAs. Hence, increased dietary 
intake of n-3 PUFAs may shift the balance of the 
eicosanoid production to a putatively less infl am-
matory profi le, such as PGE3 and LTB5. Both seal 
and fi sh oils are rich in n-3 PUFAs, but are different 
with respect to molecular localisation of the n-3 
PUFAs on the triacylglycerol (TAG) molecule. N-3 
PUFAs in seal oil are located almost exclusively at 
the end positions (sn-1 or sn-3 position) of the TAG 
molecule, whereas they are located mainly in the 
middle position (sn-2) of fi sh oil TAG (10, 11). 
During digestion and throughout the circulation, 
FAs are hydrolysed from the sn-1 and sn-3 positions 
by position specific pancreatic and lipoprotein 
lipases (12). The metabolism of structured TAGs is 
generally not infl uenced by different molecular 
localisation of n-3 PUFAs on TAG according to a 
recent review (13). However, it is not known 
whether effects of dietary TAGs on infl ammatory 
and immunological reactions depend on molecular 
localization of n-3 PUFAs.
In man, incorporation of the fatty acids into cell 
membranes by oral administration of n-3 PUFA 
requires a long-term therapeutic strategy (14). 
Nevertheless, by duodenal administration, 10 days 
treatment with n-3 PUFA rich seal oil was enough 
to markedly alleviate joint paint in patients with 
IBD (15, 16). The intervention improved symp-
toms, fatty acid profi le of red blood cells and rectal 
mucosa, and enhanced health related quality of life 
(17), but did not signifi cantly change infl ammation 
markers. In another double blind short-term (14-
day) study using oral administration of seal oil and 
soy oil in psoriatic arthritis patients, we found no 
signifi cant difference in symptomatic effects of the 
two oils (18). A major difference between the latter 
study in patients with psoriasis (18) and the prior 
studies in IBD-patients (15–17), was the mode of 
administration (oral versus duodenal). 
Based on these short-term studies, we aimed to 
test whether prior short-term dietary supplementa-
tion with fi sh or seal oils (n-3 rich PUFAs), or soy 
oil (n-6 rich PUFAs) in addition to a background 
diet would infl uence the development of colonic 
infl ammation following subsequent exposure to 
dextran sulfate sodium (DSS) in rats. To our knowl-
edge, this is the fi rst study where the effect of seal 




Forty-eight adult male Wistar rats (Møllegaard 
and Blomholtgaard, Ry, Denmark), with mean 
weight 371 g, were singly housed in Macrolon III 
cages. Access to food, Beekay rodent low protein 
diet consisting of cereal products (88,5%), soy 
protein (6%), animal proteins (2,5%), soy oil 
(0,5%) and vitamin-, mineral- and amino acid-
supplementation (2,5%) (B&K Universal AS, 
Nittedal, Norway), was ad libitum. The nutrient 
and fatty acid composition of the standard diet is 
given in Table 1. Tap water was given ad libitum 
if not otherwise stated. Animals were maintained 
at controlled temperature (21 ± 1 °C) with a 12 h 
light and 12 h dark cycle, relative humidity 55 ± 





Crude fi bre 5.02%
Ash 5.22%
NFE 63.62%
Dig. crude oil 2.67%







Gross energy 14.91 MJ/kg









NFE = nitrogen free extract. Dig = digestible, based on in-vitro 
digestibility analysis (according to manufacturer). Fatty acids given 
are % of crude oil. All data according to the product specifi cation 
from manufacturer.
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5% and 20 air changes per hour. The protocol was 
approved by the Norwegian Animal Research 
Authority.
Induction of DSS colitis
Acute colitis was induced by 50 g/L of DSS (MW 
44 000, TdB Consultancy AB, Uppsala, Sweden) 
given in distilled drinking water for 7 successive 
days. The solution was refreshed every second day 
and consumption was accordingly measured.
Experimental design
Following 7 days (day 1–7) of acclimatisation (daily 
handling for 5 minutes by the same individuals), the 
48 animals were randomly divided into 6 groups of 
8; group 1: control (no intervention), group 2: sham 
(1 mL distilled water once daily by gavage day 8–
21), group 3: DSS, group 4: soy oil + DSS, group 
5: seal oil + DSS and group 6: fi sh oil + DSS. In the 
last three groups, fi rst, oil was given by gavage for 
7 days (day 8–14), and then the rats were exposed 
to DSS (day 15–21) without oil gavage. Gastric 
gavage was performed by using a feeding tube (CH 
06, 50 cm, Maersk). Animals were held in the scruff 
of the neck and the feeding tube was placed into the 
stomach (around 8 cm from the tooth row). 
The seal oil (Rieber Skinn A/S, Bergen, Norway) 
was a mixture of crude oil from harp seal (Phag-
ophilus groenlandicus) and hooded seal (Cystophora 
cristata). The seal oil group received 0.07 g of eicos-
apentaenoic acid (EPA, 20:5n-3), 0.03 g of docosap-
entaenoic acid (DPA, 22:5n-3) and 0.07 g of docosa-
hexaenoic acid (DHA, 22:6n-3), the fi sh oil group 
(cod liver oil, Peter Møller, Oslo, Norway) received 
0.08 g of EPA, 0.01 g of DPA and 0.12 g of DHA, and 
the soy oil group (Mills DA, Oslo, Norway) received 
0.5 g of linoleic acid (LA, 18:2n-6) and 0.06 g of α-
linolenic acid (ALA, 18:3n-3) per day. The FA compo-
sition, levels of vitamin A and E and lipid peroxidation 
assessed by an in vitro method determining thiobar-
bituric acid reactive substances (TBARS) in the seal, 
fi sh and soy oils are presented in Table 2.
On day 23, all rats were anaesthetised by subcu-
taneous injection of a combination of fentanyl 
citrate + fl uanisone (Hypnorm®, Janssen Pharma-
ceutica, Beerse, Belgium) and midazolam 
(Dormicum®, Roche, Oslo, Norway) (Fentanyl 
citrate 0.079 mg/mL, fluanisone 2.5 mg/mL, 
midazolam 1.25 mg/mL), at a dose of 0.2 mL/100g. 
Thoracotomy, cardiac puncture and exsanguination 
were performed. 
Sample collection and analysis 
Blood was drawn into a heparin-containing 
Vacutainer, placed on ice for 10 minutes and then 
centrifuged at 2000 rpm for 10 minutes at 4°C. 
Aliquots of red blood cells were stored at −80 °C 
for future analysis. 
Quantitative FA composition was analysed in 
red blood cells (using biological sample parallels) 
and oils. The samples were dissolved in chloro-
form/methanol (2:1, w/w) and a 19:0 methyl ester 
was added as internal standard. The samples were 
fi ltered, saponifi ed and methylated using 20% BF3 
in methanol. FA composition of total lipids was 
analysed using methods described by Lie and 
Lambertsen (19) where the methyl esters were 
separated using a Trace GC 2000 gas chromato-
graph (“cold on column” injection, 6025 °C/
min16025 °C/min190 25 °C/min 220 °C), equipped 
with a 50 m CP-sil 88 (Chrompack) fused silica 
capillary column (id: 0.32 mm). The FAs were 
identifi ed by retention time using standard mixtures 
of methylesters (Nu-Chek, Elyian, USA), and the 
quantitative FA composition was calculated using 
an integrator (Totalchrom), connected to the Gas 
Liquid Chromatography (GLC)-system. 
Faeces were collected on day 22 and then stored 
at −20 °C until analysis of granulocyte marker 
protein (GMP), a marker of intestinal infl amma-
tion. Briefl y, 1 g of faecal material was diluted in 
4 mL extraction buffer and thoroughly homoge-
nized using an Ultra Turrax (20,000 rpm) before 
centrifugation at 45000 g for 20 min. The upper 
halves of the supernatants were carefully harvested 
and ran on a standard one-step ELISA as described 
previously (20).
Tissue preparation and histological 
assessment 
Colon from the colocecal junction to the anal verge 
was removed for histological examination. The length 
of the colon was recorded. The colon was rinsed with 
phosphate-buffered saline buffer, opened longitudi-
nally and divided into one proximal and one distal 
segment, which were fi xed in 10% formalin and 
embedded in paraffi n. Eight pieces per segment were 
stained with haematoxylin and eosin. 
Colonic crypt and infl ammatory scores were 
determined according to a validated scoring system 
(21), and examined by a pathologist unaware of the 
experimental protocol. Crypt injury was scored as; 
grade 0: intact crypts, grade 1: loss of bottom one 
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third of crypts, grade 2: loss of bottom two thirds of 
crypts, grade 3: loss of entire crypt with the surface 
epithelium remaining intact, grade 4: loss of the 
entire crypt and surface epithelium. The severity of 
inflammation was scored as; grade 0: normal, 
grade 1: focal infl ammatory cell infi ltration, grade 
2: infl ammatory cell infi ltration, gland dropout and 
crypt abscess. Both scores include a measure of 
involvement as follows; grade 1: 1–25%, grade 2: 
26–50%, grade 3: 51–75%, grade 4: 76–100%. The 
score is the product of either the crypt or infl amma-
tion grade by the involvement grade. The fi nal crypt 
and infl ammation scores are the averages of all 
individual scores of 16 pieces per colon. 
Statistical Analysis
Data were analysed using the GraphPad Prism 
version 4 (GraphPad Software Inc., USA) statis-
tical software package. Results are presented as 
mean ± standard error of mean. Differences 
between means were evaluated with one-way 
ANOVA and Bonferroni post-test for selected pairs 
of columns. P values less then 0.05 were considered 
statistically signifi cant.
Results
There were no signifi cant differences in any param-
eter between the control (no intervention) group and 
the sham group. These two groups were therefore 
merged into one group called controls in the presen-
tation of results. One rat in the seal oil group bit off 
a piece of the distal part of the feeding tube on day 
14, but the tube was visible at the upper part of larynx 
and was removed under isofl uran anaesthesia. The 
experiment was completed without mortality. 
DSS intake
Total intake of water with DSS was similar in the 
DSS group (157 ± 11.5 mL) and the oil + DSS groups 
(soy oil + DSS: 146 ± 14.2 mL; seal oil + DSS: 157 
± 10.7 mL and fi sh oil + DSS: 152 ± 8.1 mL).
Weight change
From the start of DSS treatment to sacrifi ce, weight 
loss was observed in all groups (DSS: –11.3 ± 4.0 g; 
soy oil + DSS: –7.6 ± 2.3 g; seal oil + DSS: –14.1 
± 4.2 g and fi sh oil + DSS: –23.4 ± 6.7 g), except in 
control rats (1.4 ± 1.9 g). Weight change did not 
signifi cantly differ between controls and rats on 
DSS, or between groups receiving DSS and oils. 
Colon length
Colon length did not significantly differ neither 
between controls (17.6 ± 0.4 cm) and DSS group (16.8 
± 0.4 cm) nor between DSS and oil + DSS groups 
Table 2. Major fatty acids (g/100 g), vitamins A and E and TBARS.
 Seal oil Fish oil Soy oil
Σ saturated 12.9 15.4 13.4
16:1n-7 11.6 6.1 n.d
18:1n-9 16.3 13.7 17.5
20:1n-9 7.5 10.2 0.2
Σ monoenes 47.6 46.0 19.0
18:2n-6 1.4 1.5 49.7
20:4n-6 0.4 0.4 n.d
Σ ω-6 1.8 2.2 49.7
18:3n-3 0.7 0.8 5.5
20:5n-3 6.6 7.5 n.d
22:5n-3 3.1 1.1 n.d
22:6n-3 7.4 12.4 n.d
Σ ω-3 21.0 25.1 5.5
n-6/n-3 0.1 0.1 9.0
Sum vitamin A 1.4 mg/100g 4.8 mg/100g n.d
α-tocopherol 5.4 mg/100g 309 mg/100g 17.1 mg/100g
TBARS 15.3 nmol/g WW 13.8 nmol/g WW n.d
Sum vitamin A  = all-trans retinol + 13-cis retinol +  3-Dehydroretinol.
TBARS = thiobarbituric acid reactive substances. n.d  = not detected. 
WW = wet weight.  
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(soy oil + DSS: 16.3 ± 0.4 cm; seal oil + DSS: 16.1 ± 
0.5 cm and fi sh oil + DSS: 15.4  ± 0.6 mL). However, 
there was a tendency to shorter colons in groups 
with colitis, especially in fish oil + DSS, as 
compared to controls. 
Histology of the colon
Microscopic evaluation of colonic sections showed 
indications of colitis in all rats receiving DSS. 
Changes were most prominent in the distal colon 
with areas of erosions, crypt distortion and infl am-
matory cell infi ltration as previously described (22) 
(Fig. 1). Soy oil signifi cantly increased mean crypt 
score (p < 0.04), but not mean infl ammation score, 
in rats with DSS-induced colitis. Such signifi cant 
change was not seen in rats receiving n-3 FAs (seal 
or fi sh oil) + DSS (Fig. 2).
Granulocyte marker protein
After 7 days of DSS intake, faecal GMP levels 
increased signifi cantly in rats on DSS (63.6 ± 19.5 
mg/L) as compared with controls (7.8 ± 2.6 mg/L) 
(p < 0.01). There was no signifi cant difference 
between DSS and oil + DSS groups. However, high 
faecal GMP levels were observed in rats receiving 
seal (84.8 ± 25.1 mg/L) and fish oils (88.5 ± 
28.1 mg/L), but not soy oil (51.6 ± 14.9 mg/L). 
Fatty acid composition 
Compared with controls, there was a signifi cantly 
lower n-6 to n-3 FA ratio in red blood cells of DSS 
and DSS + oil groups (p < 0.001) (Table 3). 
Discussion
In the present study short-term pretreatment with 
either n-3 PUFA rich seal or fi sh oils as a supple-
ment to an n-6 PUFA rich (soy based) standard diet 
did not protect against subsequent induction of 
colitis by DSS in rats. Contrary to what we hypoth-
esized, the administration of all PUFAs tended to 
aggravate the inflammation. The oil-induced 
changes were not signifi cant except for crypt injury 
score in the group receiving soy oil.
Based on the results from our previous studies 
(15–18), we expected a protective effect of short-
term administration of n-3 PUFAs on the develop-
ment of colonic infl ammation. The lack of protection 
against colitis might be due to the short duration of 
oil supplementation (7 days) and the low dose of 
n-3 PUFAs given as a supplement to an n-6 PUFA 
rich standard diet. Other studies used at least 13 days 
oral administration or 2 weeks rectal enema (4, 11, 
23) allowing the fatty acids to be incorporated into 
membranes. Such incorporation into red blood cells 
needs several weeks (14). 
It is generally recommended that the human diet 
should return to a more balanced ratio of n-6 to 
n-3 FA (24). A ratio closer to 4 to 1 rather than the 
ratio of 20–15 to 1 as provided by current Western 
diet is supposed to be benefi cial also for patients 
with IBD. An epidemiological study found 
increased intakes of n-6 FAs with a concomitant 
increase in the ratio of n-6 to n-3 FAs to be associ-
ated with increased occurrence of CD (25). A recent 
clinical study found reduced remission rates with 
increasing fat content when soy oil-based enteral 
feeds were administered to patients with active CD 
(26). Induction of colitis by DSS decreased the 
Table 3. Fatty acid composition in red blood cells (mg/g) in study groups. Means (SEM).
Fatty acid Controls DSS Soy oil + DSS Seal oil + DSS Fish oil + DSS
18:2 n-6 0.22 ± 0.03 0.22 ± 0.02 0.24 ± 0.01 0.24 ± 0.02 0.25 ± 0.02
20:3 n-6 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
20:4 n-6 0.55 ± 0.07 0.57 ± 0.03 0.59 ± 0.02 0.52 ± 0.09 0.54 ± 0.02
∑ n-6 0.80 ± 0.07 0.79 ± 0.05 0.83 ± 0.02 0.78 ± 0.08 0.81 ± 0.03
18:3 n-3 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
20:5 n-3 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
22:5 n-3 0.03 ± 0.01 0.06 ± 0.10 0.03 ± 0.01 0.04 ± 0.01 0.04 ± 0.00
22:6 n-3 0.05 ± 0.01 0.06 ± 0.01 0.06 ± 0.01 0.07 ± 0.01 0.09 ± 0.01
∑ n-3 0.08 ± 0.01 0.12 ± 0.05 0.10 ± 0.01 0.13 ± 0.01 0.14 ± 0.00
n-6/n-3 10.0 ± 0.01  6.6 ± 0.05*  8.3 ± 0.01*  6.0 ± 0.02*  5.8 ± 0.00*
* indicates p < 0.001
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Figure 1. H&E, 10X. a) Histologic appearance of the normal colonic mucosa of healthy control rat (intact crypts). b) Colonic mucosa of rat 
with DSS colitis showing crypt loss, infl ammatory infi ltration and crypt abscesses. c) Colonic mucosa of a rat which received soy oil and 
DSS. d) Colonic mucosa of a rat which received seal oil and DSS. e) Colonic mucosa of a rat which received fi sh oil and DSS (c, d and e 
show similar fi ndings as in b).
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ratio of n-6 to n-3 FAs in all groups, possibly due 
to consumption of n-6 FAs for generation of pro-
infl ammatory prostaglandins and leukotriens. Even 
with n-3 PUFA rich seal or fi sh oils supplementa-
tion, the ratio remained high (around 6 to 1). 
Possibly due to the fact that the rats’ standard diet 
had a high n-6 to n-3 FA ratio (11 to 1), both base-
line (control groups) and fi nal n-6 to n-3 ratios 
(experimental groups) were too high to disclose 
potential protective effects of n-3 PUFA rich oil 
supplementation. 
DSS in the drinking water is a widely used 
experimental model of colitis (27). There are few 
studies testing effects of fi sh oil in DSS-induced 
colitis. Camuesco et al reported benefi cial effects of 
adding fi sh oil to an olive oil diet (28). In another 
study, the effect of fish oil was compared with 
Lyprinol (Lipid extract of New Zealand Green Lipped 
Mussel) and olive oil in mice (23, 29). The results 
showed no signifi cant benefi t of fi sh oil compared 
with Lyprinol or olive oil. In our study, fi sh oil was 
richest in n-3 PUFAs and provided the lowest n-6 to 
n-3 ratio in blood, but still the fi sh oil + DSS group 
lost most weight, had the shortest colon and the 
highest GMP value (not signifi cant). The level of 
α-tocopherol, added as an antioxidant for protection 
of PUFAs against lipid peroxidation, was in fact 57 
times higher in the fi sh oil compared with the seal oil 
with quite similar TBARS values. Whether the crude 
seal oil contained additional benefi cial substances 
compared with refi ned marine oils is not known. 
Amending regulations on contaminants prohibit the 
use of crude marine oils in clinical trials.
Faecal GMP, which corresponds to calprotectin 
in humans, has been used to monitor gut infl am-
mation (30, 31). GMP extracted from faeces is a 
non-invasive marker of gastrointestinal infl amma-
tion in rats, and is derived from neutrophils and 
monocytes. In our study, exposure to 5% DSS 
induced histological infl ammation, elevated faecal 
GMP concentration and loss of weight similar to 
that reported by others (27, 31). Treatment in all 
oil groups tended to aggravate the colitis, however, 
the change was signifi cant in the soy oil group only. 
The signifi cantly increased crypt injury score with 
soy oil might indicate a deleterious effect of soy 
oil because loss of crypts is a typical and early sign 
of DSS induced damage (32). Notably, while rats 
may convert ALA to EPA and DHA rather easily, 
humans can not. Relatively high ALA concentra-
tions in soy oil may therefore mask deleterious 
effects of a high LA diet much more in rats than in 
humans (33). The oils were not oxidised according 
to TBARS measurement, and thus probably did 
not cause oxidative injury. Whether the use of a 
gastric gavage might have stressed the rats and thus 
contributed to the more severe colitis in the 
DSS + oil groups compared with DSS group is 
possible since stress is known to contribute to the 
severity of both experimentally induced colitis 
and ulcerative colitis (34). Control (no gavage) and 
sham (with gavage day 8–21) groups was however 
not different, but we have no additional sham + DSS 
group enabling us to conclude whether the oils per 
se or the gavage procedure per se, contributed to the 
development of colitis.









































Figure 2. Effect of DSS and n-3 or n-6 polyunsaturated fatty acids on histological crypt and infl ammation scores. Results are expressed as 
mean ± SEM. Symbols mean signifi cant difference, p < 0.05.
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In conclusion, short-term pretreatment with 
seal or fi sh oils as a supplement to a n-6 PUFA 
rich (soy based) standard diet did not protect 
against subsequent induction of colitis by DSS in 
this rat model. Further studies are required to 
elucidate the effects of different n-6 to n-3 FA 
ratios in the diet and tissues before subsequent 
induction of colitis by DSS. 
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